AU4327300A - Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension - Google Patents
Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertensionInfo
- Publication number
- AU4327300A AU4327300A AU43273/00A AU4327300A AU4327300A AU 4327300 A AU4327300 A AU 4327300A AU 43273/00 A AU43273/00 A AU 43273/00A AU 4327300 A AU4327300 A AU 4327300A AU 4327300 A AU4327300 A AU 4327300A
- Authority
- AU
- Australia
- Prior art keywords
- compositions
- methods
- vascular disease
- pulmonary hypertension
- peripheral vascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000018262 Peripheral vascular disease Diseases 0.000 title 1
- -1 Prostaglandin compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000002815 pulmonary hypertension Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
- C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
- C07C405/0075—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system
- C07C405/0083—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system which is only ortho or peri condensed, e.g. carbacyclins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12725499P | 1999-03-31 | 1999-03-31 | |
US12725599P | 1999-03-31 | 1999-03-31 | |
US60127254 | 1999-03-31 | ||
US60127255 | 1999-03-31 | ||
PCT/US2000/008240 WO2000057701A1 (en) | 1999-03-31 | 2000-03-29 | Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4327300A true AU4327300A (en) | 2000-10-16 |
Family
ID=26825478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU43273/00A Abandoned AU4327300A (en) | 1999-03-31 | 2000-03-29 | Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1164846A1 (en) |
JP (1) | JP2003523935A (en) |
KR (1) | KR20020012169A (en) |
CN (1) | CN1354622A (en) |
AU (1) | AU4327300A (en) |
CA (1) | CA2359652A1 (en) |
WO (1) | WO2000057701A1 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6242482B1 (en) | 2000-06-05 | 2001-06-05 | United Therapeutics Corporation | Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure |
CA2959852A1 (en) | 2003-05-22 | 2005-01-27 | United Therapeutics Corporation | Compounds and methods for delivery of prostacyclin analogs |
KR101161889B1 (en) * | 2003-12-16 | 2012-07-02 | 유나이티드 쎄러퓨틱스 코포레이션 | Use of treprostinil to treat and prevent ischemic lesions |
US20090124697A1 (en) | 2003-12-16 | 2009-05-14 | United Therapeutics Corporation | Inhalation formulations of treprostinil |
AU2006219152B2 (en) * | 2005-03-04 | 2011-02-24 | Sucampo Ag | Method and composition for treating peripheral vascular diseases |
BR112014003240A2 (en) * | 2011-08-12 | 2017-03-01 | Ascendis Pharma As | sustained release prostacyclin composition |
KR101997939B1 (en) | 2011-08-12 | 2019-07-08 | 아센디스 파마 에이에스 | Carrier-linked treprostinil prodrugs |
JP6542128B2 (en) | 2013-01-11 | 2019-07-10 | コルセア ファーマ インコーポレイテッド | Treprostinil Prodrugs |
US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
CA3212313A1 (en) | 2013-03-14 | 2014-10-02 | United Therapeutics Corporation | Solid forms of treprostinil |
JP2016516693A (en) | 2013-03-15 | 2016-06-09 | ユナイテッド セラピューティクス コーポレイション | Salt of treprostinil |
KR102238501B1 (en) | 2013-03-25 | 2021-04-08 | 유나이티드 세러퓨틱스 코오포레이션 | Process of making prostacyclin compounds with linker thiol and pegylated forms |
DK3060041T3 (en) * | 2013-10-25 | 2021-03-22 | Insmed Inc | PROSTACYCLINE COMPOUNDS |
JP2017517550A (en) | 2014-06-13 | 2017-06-29 | ユナイテッド セラピューティクス コーポレイション | Treprostinil preparation |
WO2016064764A1 (en) | 2014-10-20 | 2016-04-28 | United Therapeutics Corporation | Synthesis of intermediate for producing prostacyclin derivatives |
US10343979B2 (en) | 2014-11-18 | 2019-07-09 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
US9643911B2 (en) * | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
EP3515430A1 (en) | 2016-09-26 | 2019-07-31 | United Therapeutics Corporation | Treprostinil prodrugs |
AU2017361521B2 (en) | 2016-11-21 | 2020-08-27 | Bruker Spatial Biology, Inc. | Chemical compositions and methods of using same |
EP3498283A1 (en) | 2017-12-14 | 2019-06-19 | Ipsol AG | Glycosidic derivatives of treprostinil |
CA3138530A1 (en) | 2019-04-29 | 2020-11-05 | Insmed Incorporated | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
JP2022546314A (en) | 2019-08-23 | 2022-11-04 | ユナイテッド セラピューティクス コーポレイション | Treprostinil prodrug |
WO2021211916A1 (en) | 2020-04-17 | 2021-10-21 | United Therapeutics Corporation | Treprostinil for use in the treatment of intersitial lung disease |
EP4161909A1 (en) | 2020-06-09 | 2023-04-12 | United Therapeutics Corporation | Fumaryl diketopiperidine prodrugs of treprostinil |
CN117062605A (en) | 2020-12-14 | 2023-11-14 | 联合治疗公司 | Methods of treating diseases using treprostinil prodrugs |
JP2024510930A (en) | 2021-03-03 | 2024-03-12 | ユナイテッド セラピューティクス コーポレイション | A dry powder composition of treprostinil and its prodrugs and further comprising (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (FDKP) dry powder composition |
KR20240141319A (en) | 2022-02-08 | 2024-09-26 | 유나이티드 쎄러퓨틱스 코포레이션 | Treprostinil iloprost combination therapy |
US20240287105A1 (en) | 2023-01-19 | 2024-08-29 | United Therapeutics Corporation | Treprostinil analogs and related methods of making and using |
-
2000
- 2000-03-29 EP EP00923092A patent/EP1164846A1/en not_active Withdrawn
- 2000-03-29 CN CN00804756A patent/CN1354622A/en active Pending
- 2000-03-29 CA CA002359652A patent/CA2359652A1/en not_active Abandoned
- 2000-03-29 JP JP2000607467A patent/JP2003523935A/en active Pending
- 2000-03-29 AU AU43273/00A patent/AU4327300A/en not_active Abandoned
- 2000-03-29 KR KR1020017012628A patent/KR20020012169A/en not_active Application Discontinuation
- 2000-03-29 WO PCT/US2000/008240 patent/WO2000057701A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2003523935A (en) | 2003-08-12 |
EP1164846A1 (en) | 2002-01-02 |
KR20020012169A (en) | 2002-02-15 |
WO2000057701A1 (en) | 2000-10-05 |
CN1354622A (en) | 2002-06-19 |
CA2359652A1 (en) | 2000-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4327300A (en) | Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension | |
AU3998400A (en) | Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor | |
AU2002218742A1 (en) | Application of photochemotherapy for the treatment of cardiac arrhythmias | |
AU5963900A (en) | Muteins of bilin-binding protein | |
AUPR638101A0 (en) | Composition and method for treatment of disease | |
AU2268401A (en) | Novel succinate compounds, compositions and methods of use and preparation | |
AU2003200722A1 (en) | Compositions and methods for the treatment of tumor | |
AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
AU2495200A (en) | Compositions and methods for the treatment of tumor | |
AU2003200731A1 (en) | Compositions and methods for the treatment of tumor | |
HK1042247A1 (en) | Use of benzazepine-n ethanoic acid derivatives forpreparation of medicament for treating pulmonary hypertension. | |
AUPR101600A0 (en) | Compositions and methods for diagnosis and treatment of cardiovascular disorders | |
AU2001257406A1 (en) | Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941 | |
AU1953701A (en) | Methods and compositions for treatment of inflammatory disease | |
AU1878201A (en) | Composition for the treatment of damaged tissue | |
AU2001247471A1 (en) | Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones | |
AU4228000A (en) | Methods and compositions for the treatment and prevention of lung disease | |
AU5179800A (en) | Mycolactone and related compounds, compositions and methods of use | |
AUPP870999A0 (en) | Method of treatment of equine disease | |
AU7670700A (en) | Method for improving the stay-on properties of cosmetic compositions | |
AU4450100A (en) | 225Ac-heha and related compounds, methods of synthesis and methods of use | |
AU3757200A (en) | Treatment of pulmonary hypertension | |
AU5553200A (en) | Process for the preparation of paroxetine and structurally related compounds | |
AU4225500A (en) | Methods and compositions for the treatment and prevention of lung disease | |
AU4034800A (en) | Novel compositions and methods for prevention and treatment of protozoal disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |